Register Login

Marstacimab Anti-TFPI Moab Submitted for FDA and EMA Approval

Pfizer has applied to the US FDA and the European Medicines Agency [EMA] for approval of their monoclonal antibody anti-tissue factor pathway inhibitor [TFPI] therapeutic, marsticimab, a competitor to Novo Nordisk’s concizumab, approved by Health Canada under the trademark Alhemo┬«, and awaiting FDA and EMA approval. The FDA anticipates an FDA ruling in the fourth quarter of 2024 and an EMA ruling in 2025. Click here for Pfizer’s December 2023 press release.

Comments (0)
Bleeding Disorders

No comments here.

Leave a Reply